Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21013963 | 0.82 | PIK3CA (0.42) | ALDH1A1MAPTL3MBTL1NPSR1CYP1A2 | |
| SCHEMBL17859918 | 0.79 | PIK3CA (0.55) | ALDH1A1MAPTL3MBTL1CYP1A2KMT2A | |
| SCHEMBL2488434 | 0.76 | KMT2A (0.49) | ALDH1A1MAPTTSHRNPSR1CYP1A2 | |
| SCHEMBL17859826 | 0.76 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1TSHRCYP1A2CYP2C19 | |
| SCHEMBL12986387 | 0.74 | KMT2A (0.46) | ALDH1A1MAPTL3MBTL1NPSR1CYP1A2 | |
| SCHEMBL11926409 | 0.73 | ALDH1A1 (0.49) | ALDH1A1MAPTL3MBTL1TSHRNPSR1 | |
| SCHEMBL21697556 | 0.73 | CYP1A2 (0.43) | ALDH1A1L3MBTL1TSHRNPSR1CYP1A2 | |
| SCHEMBL19494244 | 0.72 | TSHR (0.44) | ALDH1A1L3MBTL1TSHRCYP1A2CYP2C19 | |
| SCHEMBL3991404 | 0.71 | MAPT (0.51) | ALDH1A1MAPTL3MBTL1NPSR1CYP1A2 | |
| SCHEMBL17673774 | 0.70 | MAPT (0.56) | ALDH1A1MAPTL3MBTL1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| EP-3441387-A1 | PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| EP-3235816-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095833-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349568-A1 | 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 3832/4885MAPT 2206/4885L3MBTL1 1666/4885 |
| US-10227324-B2 | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 3832/4885MAPT 2206/4885L3MBTL1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.